ImmunityBio, Inc. — A real product, one decisive readout, and a platform still to be proven

01Summary

ANKTIVA is a genuine commercial product — eight consecutive quarters of growth to $50.7m¹, roughly 99% gross margin, a permanent J-code, NCCN listings in two settings, and a narrowing operating loss. The investment question is not whether the product works. It is how fast it can scale, and against what.

Three conclusions from this work differ from both the standard bull and bear framings of the name.

First, the binding constraint is evidence and timing, not BCG supply. Supply is real and it shapes the business ANKTIVA has today: "BCG-unresponsive" is a status that requires documented adequate prior BCG, so the shortage constricts the eligible pool for every second-line agent. But it does not gate the growth thesis. ANKTIVA in the BCG-naive setting rides on the same BCG schedule a high-risk patient already receives — it adds no incremental demand — and urologists already prioritise high-risk naive patients for BCG during shortages. What actually decides 2028 is whether QUILT-2.005's full readout holds up and how fast FDA moves.

Second, IMFINZI's head start is weaker than it appears. AstraZeneca reached the BCG-naive market first, in May 2026, with randomised Phase 3 data ANKTIVA cannot match. But it requires intravenous infusion every four weeks for thirteen cycles in a disease managed by community urologists who cannot administer it. Pembrolizumab was approved in NMIBC in 2020 with no locally administered competitor and drew 126 patients²⁷ in two years. Site of care may matter more here than trial data.

Third, the company is closer to self-funding than its going-concern⁴¹ language implies. Operating cash flow turns positive in Q1 2028 with a cash trough near $123m — tight but not forced. The larger issue is the $480m convertible maturing 31 December 2027³⁶, one quarter ahead of that trough.

A fourth point deserves more weight than it usually receives. ANKTIVA's subcutaneous approvals for lung cancer in Saudi Arabia and the UAE are not merely a small lung-cancer opportunity. They put an injectable, systemically-administered vial on a pharmacy shelf in jurisdictions where off-label prescribing is lawful — which makes every future NSCLC approval a lawful supply channel for immune reconstitution in a far larger population. That is examined in Section 07a.

02The business as it stands

ANKTIVA (nogapendekin alfa inbakicept) is an IL-15 superagonist approved April 2024³ for BCG-unresponsive NMIBC with carcinoma in situ, administered intravesically in combination with BCG. That combination requirement is the most consequential fact about the franchise and recurs throughout this report.

The pattern that matters: percentage growth decelerates while absolute dollar adds hold flat near $6m. That is the signature of a business adding patients at a constant rate into a constrained pool, not one compounding. Operating burn — derived on a quarter-standalone basis — improved $13.2m year-on-year while operating expenses grew — the improvement is revenue-driven operating leverage, which is the healthy version.

Unit economics

WAC is $35,800 per 400mcg dose¹⁵, unchanged since launch — FY2025²'s growth was volume, not price. At the reported ~17% gross-to-net, net realisation is approximately $29,714 per dose. The label permits up to 30 doses over 37 months (roughly $891k net lifetime), but QUILT-3.032 persistence implies an expected 12.8 doses, or about $380k net per patient. Q2 2026 revenue therefore represents roughly 1,700 doses and, in quasi-steady state, on the order of 130–200 new patient starts per quarter — 550–800 annually against a BCG-unresponsive addressable pool of roughly 12,000–16,000. Penetration is 10–15%, and the runway inside the current label is real.

The gross margin, and why it persists

ANKTIVA reports cost of sales of $0.298m against $50.7m of revenue in Q2 2026 — a gross margin above 99%. No commercial biologic sustains that on normal economics, and the reason matters for the cost line in this model.

Manufacturing costs incurred before FDA approval were expensed to research and development rather than capitalised, because inventory was not yet probable of future economic benefit. ImmunityBio completed and released drug substance sufficient for 170,000 doses in May 2024.⁴⁸ At the current consumption rate of roughly 1,700 doses a quarter, that is on the order of twenty-five years of bulk supply carried at essentially zero cost. Reported cost of sales therefore reflects fill-finish and packaging, not drug substance.

The practical consequence is that a model normalising cost of goods to the 10–15% typical of large biologics would be wrong. ANKTIVA is dosed at 400 micrograms against a $35,800 list price; the protein mass is trivial and the substance behind it is already expensed. Product cost of sales should stay in the low single digits as a percentage of revenue for years, and this model holds it there.

The offsetting consideration is that the fixed cost of the manufacturing base is not in cost of sales at all. The Dunkirk fill-finish facility spans 400,000 square feet with capacity for a million vials annually⁴⁸ against current demand of roughly 7,000 doses a year — utilisation below one percent. Under ASC 330-10-30-7 abnormal idle capacity must be expensed currently rather than capitalised, so that burden sits in research and development and selling, general and administrative expenses. Bring-up and validation costs will roll off as the facility reaches commercial status, but idle-capacity charges replace them. The model treats this as approximately neutral and does not credit an opex reduction.

03Competitive landscape

Cross-trial comparison in this field is unreliable. Every pivotal study is single-arm with different eligibility, biopsy protocols, response definitions, and follow-up. The tables below present the data with those differences visible rather than ranked, and flag BCG dependency — the axis on which ANKTIVA is structurally disadvantaged. Both ImmunityBio and Johnson & Johnson have published sponsor-funded indirect comparisons favouring their own product; these are marketing-adjacent and should not be treated as evidence.

03aThe BCG-naive share question

The single most consequential assumption in this model is how much of the BCG-naive population ANKTIVA captures. Two structural factors drive it, and neither is the one usually cited.

Site of care decides more than data does. BCG-naive high-risk NMIBC is managed almost entirely by community urologists. IMFINZI requires intravenous infusion every four weeks for up to thirteen cycles — which most urology practices cannot deliver, forcing a referral to medical oncology and the loss of both the patient relationship and the revenue. ANKTIVA is instilled in the same visit as the BCG the patient is already receiving, by the same staff, and bills under J9028¹⁰ with buy-and-bill margin retained, plus CMS pass-through status through September 2027.

The precedent is unusually clean. Pembrolizumab was approved in BCG-unresponsive NMIBC in January 2020 with no locally administered on-label competitor at the time. A claims analysis of Optum Clinformatics data covering January 2020 to December 2021 identified just 126 patients initiating treatment over two years, median age 80, median time on therapy 6.8 months. An intravenous systemic agent essentially failed to penetrate a urology-managed setting despite having the field to itself. IMFINZI faces the same structural obstacle, which materially devalues its eighteen-month head start.

Safety carries more weight here than it would elsewhere. This is a curative-intent, bladder-preservation population of otherwise-well patients. A 21% grade 3/4 rate and 27% immune-mediated AEs — thyroid dysfunction, hepatic events, dermatitis, with 45% of affected patients requiring high-dose corticosteroids — reads very differently in first-line organ preservation than in metastatic disease. The evidence nonetheless indicates safety is a secondary driver behind workflow, not the primary one.

How the penetration assumption is built. It is constructed as two factors rather than one blended rate: the fraction of eligible patients who receive any branded add-on, multiplied by ANKTIVA's share of that add-on pool. ANKTIVA likely wins a high share of the second factor on workflow and economics. The first factor stays modest, because most BCG-naive patients will remain on BCG alone — it is cheap, familiar, effective for the majority, and payers facing a $750k–$1.1m add-on across 30,000-plus first-line patients will impose prior authorisation and probable step-through.

The base case therefore carries roughly 4.5% of the eligible pool in launch year 2028, within the 3–6% band the launch analogs support and above its low end on the strength of the workflow advantage. ANKTIVA's own BCG-unresponsive launch — same company, salesforce, call point and J-code — reached mid-single-digit to low-double-digit penetration in its first full year, and the naive setting is a harder first-line add-on sale offset by a larger addressable pool. Years two and three ramp toward 7–12% and 12–20%, gated on a clean full readout, guideline inclusion and coverage. The bull case assumes 8–10% in launch year and 25–35% by year three.

04Second-line NSCLC — the larger prize and the harder fight

ANKTIVA holds accelerated approvals for metastatic NSCLC in Saudi Arabia (January 2026)³¹ and the UAE (July 2026)³² via the subcutaneous route — the first subcutaneous IL-15 superagonist approvals anywhere. There is no US or EU approval. The confirmatory Phase 3, ResQ201A²³ (ANKTIVA + tislelizumab + docetaxel versus docetaxel, 2:1, target ~462 patients, overall survival primary), began October 2025 with estimated primary completion September 2028 — implying a realistic US approval window of 2029–2030.

The TAM argument is sound: 2L+ NSCLC is worth multiples of the entire BCG-unresponsive bladder market, and a 15% share would exceed ANKTIVA's total current opportunity. The difficulty is what will already be established by 2029.

The more realistic commercial path may be combination rather than competition. ANKTIVA's mechanism — restoring NK and T-cell competence — is logically complementary to ADCs and bispecifics rather than rivalrous with them. ImmunityBio is not currently running such a registrational combination, and that is a strategic gap worth watching.

On the claim that ANKTIVA is the best approved option in this setting

It is worth stating precisely why this cannot yet be asserted, because the reasoning matters more than the conclusion. QUILT-3.055 is single-arm, n≈79–86, with median overall survival of 14.1–14.6 months. The comparators it is measured against are randomised: docetaxel plus ramucirumab produced median overall survival of 10.5 months in REVEL (n=1,253). A single-arm median cannot be set against a randomised median and read as superiority.

The reasons are structural rather than technical. QUILT-3.055 enrolled patients who had responded to prior checkpoint therapy and then progressed with no intervening treatment — a favourable-prognosis, checkpoint-sensitive group, not REVEL's all-comers. Single-arm designs additionally carry performance-status enrichment, eligibility restriction, and era effects: supportive care has improved since REVEL enrolled in 2010–2013. The oncology methods literature is consistent that single-arm results systematically overestimate benefit relative to the randomised trials that follow.

The ALC-responder analysis has the same problem in sharper form. Responders showed median overall survival of 16.2 months against 11.8 months for non-responders. But patients well enough to mount a lymphocyte response are patients well enough to live longer, and they are also on treatment longer. That is reverse causation, and only randomisation separates it from drug effect.

None of this says the drug does not work. It says the magnitude is unknown, and that ResQ201A exists precisely to find out. The defensible position is that ANKTIVA is a promising, plausibly differentiated option in a setting with genuinely poor alternatives — not that it is demonstrably the best.

05Mechanism, and what the durability data can and cannot prove

ANKTIVA is an IL-15 mutant (IL-15N72D) bound to a dimeric IL-15 receptor-α sushi domain fused to IgG1 Fc. It mimics physiological trans-presentation of IL-15, driving proliferation of NK cells and CD8+ memory T cells through the IL-2/IL-15 receptor βγc complex. Its genuine differentiator versus IL-2 is that IL-15 does not support regulatory T cells — it expands cytotoxic effectors without expanding immunosuppression.

The hypothesis that this "trains" durable antitumour immunity is plausible and is consistent with the long response durations observed. But two qualifications matter for valuation.

There is no published human immune-monitoring data from the QUILT bladder trials demonstrating memory T-cell generation, epitope spreading, or trained-immunity markers. The mechanistic backbone is a rat NMIBC model and systemic-setting data in other diseases. Durable clinical responses are consistent with immune training but do not prove it.

Intravesical administration produces no measurable systemic exposure. The FDA label states systemic concentrations were below the limit of quantitation³ (<100 pg/mL) in all patients. A bladder-cancer patient receiving ANKTIVA is therefore not receiving a body-wide immune benefit, and prescribing on that rationale would have no scientific basis. The systemic thesis lives entirely in the subcutaneous programme — a different route, a different set of trials, and a different risk profile.

Finally, the framing that chemotherapy "wears out" while immunotherapy trains is too clean. Gemcitabine is a recognised inducer of immunogenic cell death, depleting myeloid-derived suppressor cells and enhancing antigen cross-presentation — which is why J&J is testing TAR-200 with a checkpoint inhibitor. Neither agent has proven durable immune memory in human bladder tissue.

06What BCG supply does and does not constrain

Merck is the sole US supplier of TICE BCG, allocating a global capacity of 600,000–870,000 vials¹⁴ annually on the basis of historical purchasing patterns — a formula that structurally excludes small and newer practices regardless of patient need. A company-cited survey found 57% of US urologists unable to treat patients for want of it. The question is what that actually constrains.

It constrains the second-line funnel. "BCG-unresponsive" is a definitional status²⁸ requiring documented adequate prior BCG — generally five of six induction instillations plus two of three maintenance. Patients who never receive enough BCG never enter the category, so the shortage constricts the eligible pool for every second-line agent, including the BCG-free ones. This is the correct reading of ANKTIVA's linear ~$6m quarterly adds: it is partly a market-wide phenomenon, not solely company-specific execution.

It does not constrain the BCG-naive opportunity. This is the point most easily got wrong, and getting it wrong distorts the entire 2028 forecast. In the naive setting ANKTIVA is administered alongside the same BCG schedule the patient receives as standard of care — six weekly induction instillations, then three-week maintenance courses, identical to the control arm of QUILT-2.005. Adding ANKTIVA adds no incremental BCG. Moreover, AUA/SUO shortage guidance directs that scarce BCG be prioritised for exactly these high-risk naive patients, and dose-splitting lets one vial treat three. Even at an aggressive 2,500 naive patients a year, ANKTIVA-associated BCG use is a low single-digit percentage of current global supply — and that BCG is consumed with or without ANKTIVA.

One residual friction survives in the second-line setting: because ANKTIVA there does consume BCG for a patient who has already failed it, a rationing urologist has a real argument for withholding scarce supply from that combination. That pressure does not apply to first-line use.

Why TICE relief is modelled as an unlock rather than a wash

The instinctive reading is that ImmunityBio has already solved its BCG problem through the recombinant BCG expanded-access programme, so Merck's Durham capacity changes little. The billing mechanics say otherwise, and they are worth setting out because they govern the largest single upward revision in this model.

A urology practice administering TICE bills two components: the instillation procedure under CPT 51720, and the drug itself under J9030 at a national Medicare rate of $2.821 per milligram, or roughly $141 for a 50mg vial.⁴⁶ Under an expanded-access programme rBCG is investigational, carries no J-code, and is supplied free or at cost recovery — so the drug line disappears. The procedure fee survives: reporting of 51720 at full value is appropriate regardless of dose.⁴⁷

So the direct economic loss is small — roughly $141 of gross billing per instillation, and at ASP plus 6% only single-digit dollars of margin. That is precisely what makes the friction decisive. To preserve a $141 line item a practice must accept IRB review, informed consent, adverse-event reporting to the sponsor and FDA, live-biologic storage and handling, and staff training. The cost-benefit is indefensible for any practice with an alternative.

The conversion data confirms it. ImmunityBio reported nearly 200 urology practices registering for the rBCG programme in May 2025.⁴² By early 2026 the programme had roughly 58 active sites. Three-quarters of registering practices did not proceed.

The US core line accordingly decays through Q2 2027 as the current niche saturates, then re-accelerates from Q3 2027 as relief arrives — sequential adds returning to roughly $7m rather than fading toward $2m. FY2028 US core moves from $364m to $413m, and the FY2028 total from $841m to $890m.

The risk to this is timing rather than direction. Merck's guidance is that supply increases "gradually over time following local market review and approvals," and the gating sequence — prior-approval supplement, pre-approval inspection, a manufacturing cycle exceeding three months, then lot release — could push relief into 2028. A one-year delay removes most of the FY2028 benefit without changing the terminal picture.

The commercial ramp is behind the company, not ahead of it

A related assumption deserves the same treatment. It is tempting to model acceleration as the salesforce matures — the natural reading of a young commercial organisation against a competitor that arrived with an established urology field force. The evidence says that catch-up has already happened.

ANKTIVA's inflection came with reimbursement, not headcount. The first quarter carrying the permanent J-code delivered revenue of $16.5m against $7.2m the quarter before, a 129% increase, with unit volume up 150% and a single quarter's units exceeding all of the prior fiscal year.⁴³ By late 2025 the company described adoption spanning leading research centres and community urology clinics including rural areas.⁴⁴

The J-code has now been effective for eighteen months and the field organisation is built. If commercial immaturity were still suppressing demand, sequential adds would be rising. They have held between $4.9m and $6.5m for six consecutive quarters. That flat line is the post-buildout run rate, not a suppressed one — which is why no catch-up acceleration is modelled.

07Revenue model

We build from Q2 2026 actuals using a cohort and penetration approach rather than extrapolated dollar adds: $29,714 net per dose, 12.8 expected doses per patient, and a new-start ramp modulated by BCG availability. Papillary is treated as acceleration of an existing trend rather than a discrete new market, because NCCN Category 2A already permits reimbursed use. BCG-naive enters late, small, and supply-gated. NSCLC contributes nothing before 2029 and is excluded from the base case entirely.

Consensus at roughly $1.1bn for FY28 now sits level with our bull case rather than above it. The Street reaches that figure principally through the BCG-naive opportunity, modelled with an approval arriving on time and a launch curve that assumes the full readout confirms the interim. We reach a similar number by a different route — a slower bladder ramp offset by the lymphopenia and Gulf channels. The agreement on the total conceals a real disagreement about composition, and the two paths carry different risks.

07aThe Gulf private-pay opportunity

ANKTIVA holds the only NSCLC approvals anywhere — Saudi Arabia (January 2026) and the UAE (July 2026). The question is whether affluent patients with checkpoint-refractory disease, facing few remaining options, will fund treatment themselves. The arithmetic is seductive: at Gulf pricing, a few hundred patients would exceed a quarter of current US revenue. The channel deserves testing rather than dismissal.

Two distinct opportunities sit inside it, with very different feasibility.

Domestic and regional private pay

Wealthy Gulf residents and regional patients already in the catchment, treated at private hospitals, paying cash. This bypasses the NUPCO tender system entirely and is the more realistic near-term channel. The constraint is not wealth — Saudi Arabia hosts 350,000-plus millionaires and the UAE was the world's leading destination for relocating millionaires in 2025. The constraint is disease arithmetic.

Against that pool, the self-pay-capable and clinically-willing subset is perhaps 15–25%, and real-world persistence is short — median overall survival in this population is roughly 14 months, so most patients receive well under the 24-month maximum. Insurance will not close the gap: UAE mandatory plans cap at AED 150,000–250,000 and Saudi CCHI-mandated cancer cover at SAR 500,000, both below a six-figure course. This is a cash market or nothing.

Why travel is genuinely necessary for NSCLC

Patients with money and a terminal diagnosis do relocate for treatment — that much is not in doubt. The question is whether they must, and for this indication the answer is closer to yes than is generally assumed.

The obvious workaround would be for a US oncologist simply to prescribe ANKTIVA off-label — it is already FDA-approved here, and off-label prescribing of approved drugs is legal under 21 U.S.C. § 396. We tested that route and it is foreclosed on formulation grounds.

A US physician cannot pool three intravesical vials to reconstruct the Gulf dose: the concentration differs, the US product is not filled or tested for injection, and the label affirmatively prohibits the route. Nor is there reimbursement — ANKTIVA appears in no CMS-recognised compendium for NSCLC, so Medicare's off-label anticancer rule under Social Security Act §1861(t)(2)(B) is not satisfied. Self-pay would run roughly $1.87m a year at three vials per dose every three weeks, using the wrong product by a prohibited route with no liability cover. No documented case of independent US off-label use exists.

The label-expansion mechanism — why NSCLC approvals matter more than lung cancer

There is a structural consequence of the Gulf NSCLC approvals that the lung-cancer framing obscures. The subcutaneous 1.2 mg presentation is now a registered, priced, stocked product in Saudi Arabia (registration 78609-1572-260487 in the UAE; SFDA registration certificate with pricing issued in Saudi Arabia). Off-label prescribing is a lawful physician prerogative in both jurisdictions — peer-reviewed surveys describe it as common practice in the Kingdom, and nothing in the UAE framework prohibits it for a registered biologic.

The consequence: a physician in Riyadh or Dubai can lawfully purchase an injectable ANKTIVA vial and prescribe it off-label to raise the lymphocyte count of a patient who does not have lung cancer. That is impossible in the United States, where only the intravesical presentation exists and the label forbids the route. Every jurisdiction that approves subcutaneous ANKTIVA for NSCLC therefore simultaneously creates a lawful supply channel for off-label immune reconstitution. The NSCLC filing footprint is the gating variable for a much larger addressable population.

Dosing follows the expanded-access protocol — roughly 1.0 mg subcutaneously every two to three weeks, about one vial per dose. At an assumed Gulf net price of $20,000–$40,000 per vial, chronic use runs $350,000–$700,000 per patient-year; a several-month adjunctive course runs $100,000–$250,000. Those are plausible luxury-medicine numbers for a small number of patients, and the self-pay argument holds here in a way it does not in the United States: where the product is purchasable, money genuinely does solve the access problem.

The regulatory foothold that distinguishes this from prior attempts

One fact deserves more weight than the off-label framing gives it. In February 2025 the FDA granted Regenerative Medicine Advanced Therapy designation to ANKTIVA plus PD-L1 t-haNK for reversal of lymphopenia in patients receiving standard-of-care chemotherapy or radiotherapy. RMAT is available only for conditions the agency accepts as serious or life-threatening. In granting it, FDA implicitly acknowledged lymphopenia — in that defined population — as a serious condition worth treating.

That is materially more than any prior entrant in this space achieved. Interleukin-7 programmes from NeoImmuneTech and RevImmune spent more than a decade demonstrating they could raise lymphocyte counts without ever securing a comparable regulatory foothold or reaching market. ANKTIVA arrives with an approved product, a manufacturing base, commercial infrastructure, and an FDA designation that carries rolling review, intensive agency interaction, and eligibility for accelerated approval.

The condition also has an unusual profile for category creation: it is measured on every routine complete blood count, so no new diagnostic is required; its prognostic harm is documented across a dozen tumour types; and no approved therapy exists anywhere. A recognised serious condition with a validated biomarker, a free universal test, and no competitor is a genuinely rare configuration.

What RMAT does not do is solve the endpoint problem. It accelerates the path; it does not change the requirement that ImmunityBio demonstrate a clinical benefit — fewer serious infections, fewer treatment delays, or improved survival — rather than ALC correction alone. Nor does it extend beyond the designated population and combination. The bull case below therefore assumes RMAT converts into an approval in a defined chemotherapy- or radiotherapy-induced lymphopenia population, not a broad immune-reconstitution label.

On demand dynamics. Physicians do not currently treat lymphopenia — no NCCN, ASCO or ESMO guideline recommends it, and ALC is reported on every blood count but acted on by almost no one. Neutropenia became a multi-billion-dollar market because it causes acute, visible, life-threatening infection and because filgrastim gave oncologists something to do about it. Lymphopenia has neither driver: its harm is a statistical survival decrement visible only in retrospect. This is a demand-push market, and adoption will be slower than the epidemiology alone suggests.

The exception, and the logical beachhead, is radiation oncology. That community already modifies practice at real cost — proton therapy, reduced field size, vertebral-body sparing — specifically to protect lymphocytes. Clinicians who spend money on technique to preserve ALC are clinicians who believe the problem is worth solving. A pharmacological option would be new to them, and the conviction should transfer.

The base case is included in the model from 2027 as a separate line. It is not material to 2028 — but it compounds, it requires no US regulatory event, and a formal Gulf lymphopenia indication would convert the whole thing from off-label to on-label. That last item is the catalyst worth watching: ImmunityBio has stated it is pursuing label expansion for chemotherapy-induced lymphopenia and has opened discussions with both Gulf regulators about indications beyond lung and bladder.

07bThe NK cell platform and the sepsis programme

Two programmes sit behind the lymphopenia thesis and deserve separate treatment, because they are where ImmunityBio's platform claim either becomes real or does not.

The NK cell assets

The scientific logic is sound and is the strongest version of the platform argument. IL-15 is the dominant survival and proliferation cytokine for NK cells. Infused NK cells characteristically fail because they do not persist. Pairing an IL-15 superagonist with an NK infusion to sustain those cells in vivo is a coherent design, and ANKTIVA drives roughly 20-fold NK expansion with increased cytotoxicity in preclinical work.

The economics are also better than CAR-T. An off-the-shelf NK-92-derived product follows a one-donor-to-thousands-of-doses model. Autologous CAR-T lists at $370,000–$530,000 with cost of goods around $48,000–$115,000 per dose; allogeneic estimates run near $40,000 falling toward $10,000–$20,000 at scale. ImmunityBio holds GMP capacity in El Segundo and Dunkirk, New York.

Sepsis — the most endpoint-friendly indication in the pipeline

Sepsis-induced immunoparalysis is driven by apoptotic depletion of T and NK cells, and late-phase sepsis deaths are dominated by secondary infection in immunosuppressed patients. Persistent lymphopenia on day four³⁰ independently predicts 28-day and one-year mortality. The global burden is 48.9m cases and 11.0m deaths²⁹ annually — roughly a fifth of all deaths worldwide.

ImmunityBio has registered NCT07578558²², a randomised open-label Phase 2 of ANKTIVA plus standard of care versus standard of care alone in critically ill adults with sepsis and persistent lymphopenia. Roughly 50 patients, estimated start July 2026, primary completion August 2027.

This matters disproportionately for one reason: sepsis supplies a hard clinical endpoint that the lymphopenia indication lacks. Twenty-eight-day mortality is unambiguous, FDA-acceptable, and fast to read out. It sidesteps the surrogate-endpoint problem that makes an oncology lymphopenia approval so difficult. A biomarker-enriched population — patients selected for persistent lymphopenia — also addresses the heterogeneity that sank previous immunomodulatory sepsis trials.

Against that: sepsis is a graveyard. Interleukin-7, GM-CSF, interferon-gamma and checkpoint blockade have all been trialled with equivocal results. And there is a specific negative signal — an IL-15 superagonist in burn-wound sepsis expanded lymphocytes but failed to improve bacterial clearance or survival. Expanding cells is not the same as improving outcomes, and that study is the most directly relevant preclinical datapoint available.

Would the Saudi state pay?

If state health programmes fund treatment rather than individuals, the binding constraint shifts from household wealth to state budget — a materially larger and faster-moving opportunity. We tested this and the evidence came back thinner than the narrative suggests.

The state-funding pathway also has gates. A high-cost drug must clear SFDA pricing (done), mandatory health technology assessment, CCHI formulary listing, and NUPCO tender adoption — a process that since 2026 applies a "Made in Saudi" scoring weight favouring local manufacture. Saudi Arabia has funded high-cost novel therapies before: KFSHRC has treated more than 200 CAR-T patients and localised manufacturing, cutting cost per treatment from roughly SAR 1.3m to SAR 250,000. But those therapies carried US or EU approval.

What we have modelled, and what we have not

The base case now carries an explicit Gulf private-pay NSCLC line, building from $0.5m in Q4 2026 to $8m per quarter by Q4 2028 — roughly $26m across 2028, on the order of 25–40 patients on therapy at any time at Gulf reference pricing. Combined with MENA bladder revenue, the region contributes about $60m across the forecast window. That lifts FY28 from $700m to $722m: real, but 1.8%, not a re-rating.

We have not put state funding in the base case. Sized separately: if the Saudi state funded the full eligible NMIBC and NSCLC population under a managed-entry agreement at a 40–60% discount to US list, it would plausibly add $40–80m annually from 2028 — more than private pay, because volume at a discount beats a handful of patients at list. That is the upside case, and it is a call option with identifiable triggers rather than a forecast.

07cEurope and the rest of the world

Ex-US contributes roughly $159m of FY2028, about 19% of the total. Three structural facts govern that line, and the first determines whether it should be modelled at all.

How European revenue is recognised

The decisive question is whether ImmunityBio books end-market sales in Europe or a thin royalty from a licensee. The evidence points to the former. Accord Healthcare is described as a distribution partner²⁰ deploying an 85-person sales force within 100-plus commercial, medical and marketing staff across the UK, EU and EFTA — a services model, not a licence. ImmunityBio simultaneously opened a Dublin subsidiary in February 2026 explicitly to support European distribution, and post-authorisation EMA records list ImmunityBio Ireland Limited¹².

On that structure, European revenue should be modelled at ImmunityBio-captured net sales — end-market price less a distributor margin, plausibly 25–35% — rather than a royalty of a few percent. That is a large multiple of the alternative, and it is why the EU line carries real weight here.

Two structural advantages Europe has that the US does not

BCG supply is materially better. The US depends on a single supplier. Europe has access to six approved BCG substrains¹³, including Medac's Danish 1331, Serum Institute's, and the Japanese Tokyo strain. Since ANKTIVA is dosed with BCG, the constraint that suppresses US uptake is substantially absent in Europe. This is an under-appreciated positive and argues for a faster European penetration curve than the US launch produced.

The competitive field is far emptier. ANKTIVA is the first and currently only authorised therapy in the EU for BCG-unresponsive NMIBC with CIS. ADSTILADRIN received a CHMP positive opinion only in March 2026 and is not yet authorised; INLEXZO is not EU-approved; cretostimogene is earlier still. That is a first-mover window of perhaps twelve months or more in a market where the US equivalent is already crowded with four agents.

The UK outcome is a genuine negative and worth stating plainly. A NICE termination for non-submission means the product is not routinely funded in England and Wales. Whether that reflects a strategic sequencing decision or an evidence gap is not disclosed, but the practical effect is that the UK contributes almost nothing until a resubmission.

Asia — modelled near zero, but not worthless

ANKTIVA's only Asian approval is Macau, granted March 2026. No filings have been disclosed for Japan, China, Korea, Taiwan, Australia or ASEAN, so a near-zero 2028 assumption is correct.

One disclosure is worth flagging for the terminal value. The Oberland revenue-interest agreement is defined on worldwide net sales excluding China, with China defined to include the PRC and Hong Kong. A carve-out of that specificity implies China economics are structured separately and may sit with a partner or affiliate outside the main entity. Asian bladder-cancer incidence is roughly 215,700 cases a year, about 35% of the global total, with China near 92,800 and Japan near 34,600 — and Japan has both the region's highest incidence and the deepest BCG-use tradition.

The model carries a small rest-of-world line rising to $2.5m a quarter by end-2028, reflecting Macau and opportunistic named-patient revenue. The honest position is that 2028 is right and the terminal number is understated: an activated Japan filing or an identified China partner would be worth materially more than anything else in this section.

08Balance sheet and funding

Cash and marketable securities were $357.4m at 30 June against a derived quarter-standalone operating burn of $66.5m³⁵ — roughly five quarters standalone. On the base case, cumulative burn to breakeven is about $224m, troughing near $138m in Q4 2027. Tight, but not forced. Non-operating capital is ample: approximately $132m of in-the-money warrants (13.5m at $3.101, 27.96m at $3.240) and $349m of remaining ATM capacity.

The complications are structural rather than immediate. Total liabilities are $1.67bn against a stockholders' deficit of $1.05bn. The going-concern footnote persists, mitigated explicitly by the Founder's stated intent to fund operations — a dependency with no analogue among peers. The Oberland revenue interest¹⁶ skims 5.625–12.50% of ex-China net sales, so the top line converts to cash less efficiently as it scales. And the $480m related-party convertible matures 31 December 2027, one quarter before the cash trough. That is the largest dilution event in the forecast window.

09The platform question

The case for valuing ImmunityBio as more than a bladder-cancer company rests on the subcutaneous programme: NSCLC, and beyond it the lymphopenia concept — restoring absolute lymphocyte count in patients depleted by chemotherapy, radiation, age, or infection. The population is genuinely large, and low ALC is robustly associated with worse outcomes across settings.

The regulatory obstacle is that ALC is a biomarker, not a clinical outcome. FDA accepts surrogate endpoints for accelerated approval only where they are reasonably likely to predict clinical benefit, and ALC has not been validated as such. Approving "treatment of lymphopenia" as an indication would in practice require demonstrating a clinical benefit — fewer infections, fewer chemotherapy delays, improved survival — in a defined population. No registrational lymphopenia trial with a clinical endpoint has been disclosed. This is a multi-year, high-risk endeavour, and the probability of a standalone approval on ALC restoration alone is low.

The wider pipeline — pancreatic (QUILT-88), glioblastoma, HPV-positive head and neck, the M-ceNK cell-therapy platform, hAdV5 vaccine vectors — is broad on paper but largely Phase 1/2, single-arm, or not yet enrolling. Against $66.5m quarterly burn and a going-concern footnote, breadth is as much a risk as an asset: it spreads scarce capital across programmes that may all end up underpowered.

Worth noting for context: systemic IL-15 has a difficult history. Sotio discontinued its programme for insufficient efficacy, Novartis halted NIZ985 short of enrolment, and the broader cytokine field was chastened by the bempegaldesleukin failure. ANKTIVA's success has come precisely in the local, intravesical setting where systemic toxicity is avoided. The subcutaneous ambition moves it back into the arena where the class has repeatedly failed.

10Catalysts

11Valuation — a sum-of-the-parts

A single revenue multiple cannot value this company, and forcing one produces a systematically low answer. The reason is visible in a comparable: CG Oncology carries roughly $4.5–5bn of enterprise value on essentially no revenue, entirely for cretostimogene's pre-commercial NMIBC optionality. If the market pays that for one unapproved asset in this indication, then running all of ImmunityBio's value through a multiple on approved-indication revenue assigns near-zero worth to BCG-naive, NSCLC, lymphopenia and sepsis. That is not a conservative assumption; it is an incorrect one.

What follows separates the two. The commercial franchise — approved indications, generating revenue — takes a revenue multiple. Unapproved programmes are valued separately against the CGON benchmark and folded into the commercial line only when approved.

Where the commercial multiple belongs

The historical record is unambiguous about where multiples sit during the scaling phase, and it is far above where a mechanical discount would put them.

At $200m of revenue the range is 40–72x. At $500m it is 12–30x. At $1bn, 10–23x. Mature franchises with durable economics and high gross margins settle at 9–15x, not the 4.6x of the single weakest observation. Vertex is the better mature analog for a 99%-gross-margin franchise with patent protection to 2036.

The commercial multiples used below sit in the middle of that historical range: 20x in 2026 falling to 9x at maturity in the base case. IBRX-specific discounts — going-concern language, 62–66% insider control³⁹¹⁷, the Oberland revenue interest, the FDA warning letter — are real and are reflected in that positioning, applied once rather than compounded.

Pipeline optionality, benchmarked to CGON

Share count and financing, built rather than assumed

Two mechanics govern the denominator, and both are frequently mishandled. The first is that dilution and its proceeds are a single transaction. The 41.5m in-the-money warrants appear in every fully diluted count, but they also deliver roughly $132.5m of cash on exercise. The $480m convertible produces 88.4m shares, but extinguishes $480m of debt in the same motion. Counting one side without the other understates equity value twice over.

The second is that ATM issuance is a function of need and price, not a fixed schedule. A company generating cash does not draw it; a company burning cash draws it at whatever price the market offers — which is lowest precisely when the need is greatest.

The composition matters more than the total. In the bear case the warrants deliver no shares and no cash, while the convertible delivers 48.7m additional shares because it must be restructured at a distressed price. Dilution does not disappear when the stock falls — it changes form and gets worse.

The asymmetry is the point. Base and bull differ by only 11m shares, because once operating cash flow turns positive the ATM is a buffer rather than a lifeline — and at $9 a share, $100m costs almost nothing in dilution. The bear case issues 183m shares for $550m because it must raise at $3, and must raise more besides because the warrants deliver nothing. Between bear and bull the share count differs by 375m, or 29%, and essentially all of that gap is created by whether the company needs the money — which is also, unhelpfully, when the cheapest sources of it stop working.

Share growth beyond the ATM is equity compensation at roughly 1.5% a year on the outstanding base — 18m shares per two-year step. No buyback is assumed in any scenario.

The sum-of-the-parts

What this says about the current price

On base assumptions the 2026 sum-of-the-parts is $6.74 against a market price near $8.00 — so the market is paying roughly a 19% premium to a mid-range valuation of today's business plus a risk-adjusted pipeline. That is a premium, not a bubble, and it is smaller than the dispersion in the inputs. Push the commercial multiple to 25x — still inside the historical range at this revenue level — and the 2026 figure moves to roughly $8.00, precisely the current price.

The forward picture is what matters more. The base case compounds to $21.30 by 2032, roughly 2.7x from here, with a bull case at $46.39 and a bear at $3.07. The distribution remains wide and the downside remains severe, but the central case is no longer dead money — it is a mid-teens annualised return with a large upper tail, which is a materially different proposition from what the single-multiple framework implied.

12Risks

• Regulatory conduct. FDA issued a warning letter on 13 March 2026⁴ — its first full OPDP warning letter of that year — following two untitled letters to subsidiary Altor. It cited a television advertisement that never aired and a podcast appearance. The company implemented new promotional controls in April. The distinction the company would draw is fair: FDA adjudicates what is provable for promotion, not whether a claim might eventually prove true, and aspirational commentary from a founder is not the same as a marketing claim. But one cited item was a route-of-administration error, and with two applications under review the compliance bar is now materially higher.
• Litigation. Douglas v. ImmunityBio²¹ (C.D. Cal.), class period 19 January to 24 March 2026. Lead plaintiff appointed 15 July 2026. Consolidated derivative suits stayed pending the motion-to-dismiss phase.
• Competitive erosion. INLEXZO is ramping faster than ANKTIVA did from an equivalent launch point, aided by BCG independence and J&J's installed infrastructure. Cretostimogene's profile — 75.5% CR, median DOR ≥27.9 months⁷, zero grade ≥3 treatment-related events, BCG-free — is the most credible medium-term threat in CIS.
• Governance. Roughly 62–66% insider control, a related-party convertible held by an affiliate, CVRs partly held by the Founder, and a going-concern mitigation resting on his continued support. Directors have sold consistently under 10b5-1 plans; no open-market insider buying identified.
• Payer risk in the naive setting. Layering a ~$380k net regimen onto near-free generic BCG across tens of thousands of first-line patients invites step therapy and net-price concession. Bull models hold per-patient net price flat at scale; that is unlikely to survive a pharmacy benefit committee.

13Conclusion

ANKTIVA is a real product with real durability data in a niche it has penetrated only 10–15% of. The operating loss is closing, cash flow turns positive in Q1 2028 on the base case, and the company is closer to self-funding than its going-concern language suggests. Behind the commercial franchise sits an unusual configuration: a recognised serious condition with no approved therapy, a biomarker measured on every routine blood count, and an FDA designation that accepts the premise.

The sum-of-the-parts puts today's business plus a risk-adjusted pipeline at roughly $6.74 against a market price near $8.00 — a premium of about 19%, smaller than the dispersion in the inputs, and one that closes entirely at a commercial multiple of 25x, which remains inside the historical range for this revenue and growth stage. The base case compounds to $21.30 by 2032, roughly 2.7x from here, or mid-teens annualised.

That is the case for ownership. The case for care is the shape of the distribution rather than its centre. The bull path reaches $46.39 and the bear $3.07 — a fifteen-fold spread across six years, driven by a small number of binary events. QUILT-2.005's full readout rests on a 43-patient interim in which the six-month comparison did not clear significance. The convertible matures one quarter before the cash trough. Three-fifths of the equity sits with one holder whose promotional conduct has already drawn a warning letter.

None of that argues against owning it. It argues that position size should be set against the bear case rather than the base — because a $3.07 outcome is not a drawdown to be waited out, and the events that would produce it are knowable in advance. The catalysts in Section 10 are, in effect, the schedule on which this thesis will be settled.

On the platform question: the ambition is real and the science is not fanciful, but it is unproven where it counts. Sepsis in August 2027 and ResQ201A around 2029 are the two readouts that convert optionality into franchise. Until then ImmunityBio is a bladder-cancer company with credible options attached — and, on this construction, priced at roughly the value of the business with those options only partly counted.

14Appendix — sources

Every identifier below was checked against SEC EDGAR, FDA.gov, EMA.europa.eu, NICE.org.uk, ClinicalTrials.gov and DOI resolvers on 5 August 2026. Where a source carries a residual limitation it is flagged in amber at the point of citation. Nothing in the analysis rests on an unverified identifier. Footnote numbers mark the first point in the text at which each claim is made.